Lb-dtk-mv for cytomegalovirus infections

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Dec 2025: Trial started, NCT07670468
  2. 26 Jun 2026: Trial registered, NCT07670468

The trials

NCT07670468: Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.

State
Under way
Phase
Phase 1 and Phase 2
People
27 planned
Started
4 Dec 2025
Primary completion
4 Jun 2027
Arms
Experimental Group (All)
Results
None posted
  1. 4 Dec 2025: Trial started
  2. 26 Jun 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.